SUMO3 and metabolic disease: Whereas ADAP2, which binds beta tubulin and increases the stability of microtubule, and PRKG2, which is a crucial regulator of intestinal secretion and bone growth, have not been associated with weight loss or prediction models in metabolic disease settings, SUMO3 has previously been proposed to improve weight loss prediction models [56].